AtriCure, Inc. (ATRC)

AtriCure's stock has been influenced by several financial announcements and product developments. In the third quarter of 2025, AtriCure reported a 15.8% year-over-year revenue increase and improved net loss, raising its financial outlook for the year. Preliminary results for Q4 and full year 2025 showed revenue growth, with positive adjusted EBITDA projected for 2025 and 2026. The company launched several new products, contributing to revenue growth in 2025. As of February 6, 2026, the closing stock price was $37.11, with a 52-week high of $43.18 and a low of $28.29. AtriCure stock has received a consensus rating of "Moderate Buy" or "Buy" from analysts.

There is no explicit mention of significant demand seasonality for AtriCure, Inc.'s products and services. Demand is primarily driven by the global prevalence of atrial fibrillation (Afib) and related conditions, the adoption of their innovative technologies, and the ongoing need for post-operative pain management, which are generally not subject to strong seasonal fluctuations.

AtriCure, Inc. is a medical device company specializing in innovative technologies for the treatment of atrial fibrillation (Afib) and related cardiac conditions, left atrial appendage (LAA) management, and post-operative pain management. The company operates within the Health Care Equipment sector and the Surgical & Medical Instruments & Apparatus industry, focusing on cardiac arrhythmia treatment and surgical ablation. AtriCure's major products include the Isolator® Synergy™ Ablation System, AtriClip® Left Atrial Appendage Exclusion System, Hybrid AF™ Therapy, cryoICE cryoSPHERE® and cryoXT® probes, EnCompass® clamp, and other devices like multifunctional pens and linear ablation devices.

AtriCure, Inc. markets and sells its products in approximately 50 countries worldwide. The company operates directly in the United States, Germany, France, the UK, the Benelux region, Canada, and Australia, and through independent distributors in other international markets. The United States is the primary revenue generator for the company.

AtriCure's brand reputation appears positive, driven by product innovation and launches, investment in clinical trials, strong financial performance, and active social media presence. The company's continuous introduction of new and improved products enhances its reputation as a leader in medical devices for cardiac care and pain management. Investment in large-scale clinical trials demonstrates a commitment to evidence-based solutions. Strong revenue growth and improved profitability in 2025 reflect a healthy and growing company. Recent social media activity highlights the benefits of their therapies and emphasizes Afib awareness.

AtriCure, Inc.'s ownership is primarily institutional, with institutional investors holding a significant portion of the company's stock, ranging from approximately 55.13% to 81.46%. Major institutional shareholders include Vanguard Group Inc., Wellington Management Group Llp, and BlackRock, Inc. Insider ownership stands at approximately 4.37% of outstanding equity as of January 28, 2026, with key insider ownership positions held by President and CEO Michael H Carrel, Chief Operating Officer Douglas J Seith, and Chief Financial Officer Angela L Wirick. Insider ownership levels decreased by 7.14% in the 90 days ending January 28, 2026.